Cyberkinetics Neurotechnology Systems, Inc.
Cyberkinetics Neurotechnology Systems, Inc. (Cyberkinetics) is a medical device company engaged in developing products for the treatment of neurological diseases, and injuries related to the spinal cord and peripheral nerves. BrainGate Neural Interface is currently the subject of a pilot clinical trial being conducted under an Investigational Device Exemption(IDE) by the Food and Drug Administration (FDA). The system is designed to restore functionality for a limited, immobile group of severely motor-impaired individuals. It is expected that people using the BrainGate System will employ a personal computer as the gateway to a range of self-directed activities. The company operates in the United States, Canada, Israel and Europe. It is headquartered in Massachusetts, the US.